Accordingly, CALR positive patients may require higher IFN-dosages to achieve major molecular remissions contrasting the low-dose IFN treatment options used to achieve molecular remissions in half of JAK2-V617F positive ET and PV patients. The gene discussed is JAK2; the disease is acquired polycythemia vera.